“…[4] However, 18 FDG is currently the only PET contrast agent available for clinical imaging of infections, and is problematic because it lacks specificity for bacteria and has a high uptake in mammalian cells. [5a, 6] Although numerous experimental PET contrast agents have been developed for imaging bacterial infections, such as radiolabeled antibiotics, [7] antimicrobial peptides, [1a] antibodies, [8] or white blood cells, [9] these agents have had minimal clinical impact. [5a, 6] Although numerous experimental PET contrast agents have been developed for imaging bacterial infections, such as radiolabeled antibiotics, [7] antimicrobial peptides, [1a] antibodies, [8] or white blood cells, [9] these agents have had minimal clinical impact.…”